Absorption, Distribution, Metabolism and Excretion of BIA 5-1058

NCT04991181 | Completed Phase 1

• 2 other identifiers: BIA-51058-1042015-002407-28
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

the purpose of this study is:

• to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7 Megabecquerel (MBq) of radiocarbon;
• to determine the pharmacokinetics (PK) of total radioactivity (TRA) in plasma and whole blood and to assess the blood-to-plasma ratio;
• to determine the PK of BIA 5-1058 and its metabolites in plasma.

Conditions

Pulmonary Arterial Hypertension

Outcome Measures

Primary Outcomes (13)

• Cmax - Maximum observed plasma concentration

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• Tmax - Time to attain maximum observed plasma concentration

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• AUC0-t Area under the plasma concentration-time curve up to time t, where t is the last point with concentrations above the lower limit of quantitation (LLOQ)

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• AUC0-inf - Area under the plasma concentration-time curve from time 0 extrapolated to infinity

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• t1/2 - Elimination half-life

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• CLR - Renal clearance

  Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• Aeurine - Cumulative amount excreted in urine

  Cumulative Recovery of Radioactivity in Urine URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15.).

  Up to 20 days

• Ae feces - Cumulative amount excreted in feces

  Cumulative Recovery of Radioactivity in Feces FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. The pre dose sample was collected within 48 hours prior to drug administration (if collected at home before admission on Day 1, subjects recorded the time of collection and brought the sample at admission). From 48 h before returning to the clinic for the 24-hour collections, the subjects also collected stools at home and recorded the time of collection.

  Up to 20 days

• Aeair - Cumulative amount excreted in exhaled air

  Cumulative Recovery of Radioactivity in Exhaled Air. EXHALED AIR sampling was at pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168 and 240 hours post dose (with possible extension at 336 hours post-dose, if needed).

  Up to 20 days

• Aetotal - Total amount excreted, calculated as Aeurine + Aefeces + Aeair

  Cumulative Recovery of Radioactivity in Urine, Feces, Exhaled Air. URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15. FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. EXHALED AIR sampling was at pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168 and 240 hours post dose (with possible extension at 336 hours post-dose, if needed).

  Up to 20 days

• TRA t1/2 plasma

  Excretion Rates of TRA in Plasma PLASMA Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose

  Up to 20 days

• TRA t1/2 urine

  Excretion Rates of TRA in Urine URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15

  Up to 20 days

• TRA t1/2 feces

  Excretion Rates of TRA in Feces FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. The pre dose sample was collected within 48 hours prior to drug administration (if collected at home before admission on Day 1, subjects recorded the time of collection and brought the sample at admission). From 48 h before returning to the clinic for the 24-hour collections, the subjects also collected stools at home and recorded the time of collection.

  Up to 20 days

Study Arms (1)

BIA 5-1058

EXPERIMENTAL

Capsules; 400 mg; single dose; oral administration.

Drug: 400 mg BIA 5-1058

Interventions

400 mg BIA 5-1058 DRUG

Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).

Also known as: Zamicastat

BIA 5-1058

Eligibility Criteria

• Age: 18 Years - 65 Years
• Gender Eligibility Details: healthy male subjects
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Gender :male
• Age :18-65 years, inclusive
• Body Mass Index (BMI) :18.0-30.0 kg/m2 (BMI \[kg/m2\] = Body weight \[kg\] ÷ Height2 \[m2\]) at screening
• Subjects, if not surgically sterilized, were willing to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after discharge on Day 15. Adequate contraception for the male subject (and his female partner) was defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the volunteer, was acceptable
• All prescribed medication had to be stopped at least 30 days prior to admission to the clinical research center
• All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's Wort) had to be stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol, which was allowed up to admission to the clinical research center
• Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate and "powerdrinks"), commercially available orange juice (because of a potential interaction of radioactivity and vitamin C), grapefruit (juice) and tobacco products from 48 hours prior to admission to in the clinical research center until discharge (Day 15)
• Normal resting supine blood pressure and pulse showing no clinically relevant deviations as judged by the PI
• Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the PI
• All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the PI
• Willing and able to sign the ICF.

You may not qualify if:

• Employee of PRA or the Sponsor
• Evidence of clinically relevant pathology or a medical history of a major pathology as judged by the PI
• Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month)
• Mental handicap (i.e. a general or specific intellectual disability, resulting directly or indirectly from injury to the brain or from abnormal neurological development)
• History of relevant drug and/or food allergies
• Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily; the use of tobacco products in the 48 hours (2 days) prior to admission to the clinical research center on Day 1 was not allowed
• History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
• Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)
• Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
• Positive screen for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibodies or anti human immunodeficiency virus (HIV) 1 and 2 antibodies
• Participation in a drug study within 90 days prior to drug administration in the current study. Participation in more than 2 other drug studies in the 12 months prior to drug administration in the current study
• Donation or loss of more than 100 mL of blood within 90 days prior to drug administration. Donation or loss of more than 1.5 liters of blood in the 10 months prior to drug administration in the current study
• Subject with irregular bowel habits (more than 3 times a day or less than once every 2 days)
• Strenuous exercise within 96 hours (4 days) prior to admission to the clinical research center
• Significant and/or acute illness within 5 days prior to drug administration that may impact the safety of the subject, in the opinion of the PI

Sponsors & Collaborators

• Bial - Portela C S.A.: lead

Study Sites (1)

PRA Health Sciences (PRA) - Early Development Services (EDS)

Groningen, 9728 NZ, Netherlands

Location

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

zamicastat

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2021
• First Posted: August 5, 2021
• Study Start: March 31, 2017
• Primary Completion: May 24, 2017
• Study Completion: May 24, 2017
• Last Updated: August 5, 2021

Record last verified: 2021-07

Locations

NL (1)